Legal · Medical Disclaimer

Medical Disclaimer

Medical disclaimer for US Telehealth Review — editorial content is informational only and not medical advice. Compounded GLP-1 and peptide disclosures, adverse event reporting, and emergency guidance.

Published by Ranika Editorial Group LLC Last updated 2026-06-19

Important medical disclaimer

US Telehealth Review publishes editorial reviews for informational purposes only. Nothing on US Telehealth Review is medical advice. The site does not establish a doctor-patient relationship. Readers need to consult a licensed clinician before starting, stopping, or changing any medication or peptide therapy.

Not medical advice

The content on US Telehealth Review — including reviews, comparison tables, dosing references, peptide profiles, and provider scoring — is provided for general informational purposes only. It is not, and must not be construed as, medical advice, diagnosis, or treatment. The site is not a substitute for professional medical consultation. Readers are urged to consult a licensed clinician before starting, modifying, or stopping any medication, peptide, supplement, lifestyle change, or treatment program.

No doctor-patient relationship

Reading content on US Telehealth Review does not create a doctor-patient relationship between any reader and any author, editor, medical reviewer, or contributor. Our medical reviewer, Alen A. Schwartz MD, reviews editorial content for general clinical accuracy; this review does not constitute personalized medical advice to any individual reader.

Compounded GLP-1 medications

Some providers covered on US Telehealth Review dispense compounded semaglutide and compounded tirzepatide, which are not FDA-approved as finished drug products. Compounded medications are prepared by state-licensed pharmacies for individual patients pursuant to a valid prescription. Compounded products may differ from FDA-approved Ozempic, Wegovy, Mounjaro, or Zepbound in formulation, ingredients, and clinical evidence base. Readers considering compounded medications need to review the FDA's April 2026 guidance on GLP-1 compounding and discuss with their prescribing clinician.

Peptide therapies

Many peptides discussed on US Telehealth Review — including BPC-157, TB-500, CJC-1295, Ipamorelin, NAD+, MOTS-c, SS-31, Epithalon, Semax, Selank, Cerebrolysin, Dihexa, P21, Pentadeca Arginate, LL-37, KPV, DSIP, Tesamorelin, MK-677, IGF-1 LR3, GHRP-2, GHRP-6, Hexarelin, PT-141, oxytocin, kisspeptin, gonadorelin, Melanotan II, and others — are not approved by the FDA as finished pharmaceutical drugs for the indications discussed. Some are marketed as "research chemicals" and are not intended for human consumption. Others are compounded by licensed pharmacies. Readers must not interpret editorial coverage as endorsement of off-label or unapproved use. Discussion of mechanism, dosing, and clinical literature is for educational reference only.

Pricing and provider details

Pricing, peptide selection, prescriber roster, and shipping policies shown on US Telehealth Review are accurate as of each page's last-updated date. Providers change these details frequently and without notice to us. Readers need to confirm current pricing and program details on the provider's own website before making a purchase decision.

Editorial scores are opinions

Provider scores published on US Telehealth Review are editorial opinions of Ranika Editorial Group LLC's editorial team, based on the v3.0 six-pillar rubric documented on the methodology page. Scores are not endorsements of medical safety, clinical efficacy, or suitability for any individual reader.

Adverse events

If a reader experiences a serious adverse event related to any medication or peptide, the reader need to immediately contact their prescribing clinician and, if appropriate, emergency medical services. Adverse events involving FDA-regulated products can also be reported to the FDA MedWatch program at fda.gov/medwatch.

Emergency disclaimer

US Telehealth Review is not a substitute for emergency medical care. If a reader is experiencing a medical emergency, the reader need to call 911 (United States) or the local emergency number immediately.

External links

We link to provider websites, FDA pages, scientific publications, and other third-party resources for reader reference. We do not control the content of external sites and are not responsible for the accuracy or safety of information found at those external URLs. Inclusion of an external link is not an endorsement.

Contact

Questions about this disclaimer can be sent to legal@ustelehealthreview.com.

Lead Medical Researcher

Dr. Sam Saberian

Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.

Medical Reviewer

Alen A. Schwartz, MD

Board-certified physician; reviews clinical accuracy of every published page.

Editor

Julliana Edwards

Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing